The angiogenic inducer CYR61 is differentially overexpressed in breast cancer cells exhibiting high levels of Heregulin (HRG), a growth factor closely associated with a metastatic breast cancer phenotype. Here, we examined whether CYR61, independently of HRG, actively regulates breast cancer cell survival and chemosensitivity, and the pathways involved. Forced expression of CYR61 in HRG-negative MCF-7 cells notably upregulated the expression of its own integrin receptor a v b 3 (>200 times). Small peptidomimetic a v b 3 integrin antagonists dramatically decreased cell viability of CYR61-overexpressing MCF-7 cells, whereas control MCF-7/V remained insensitive. Mechanistically, functional blockade of a v b 3 specifically abolished CYR6-induced hyperactivation of ERK1/ERK2 MAPK, whereas the activation status of AKT did not decrease. Moreover, CYR61 overexpression rendered MCF-7 cells significantly resistant (>10-fold) to Taxol-induced cytotoxicity. Remarkably, a v b 3 inhibition converted the CYR61-induced Taxol-resistant phenotype into a hypersensitive one. Thus, the augmentation of Taxol-induced apoptotic cell death in the presence of a v b 3 antagonists demonstrated a strong synergism as verified by the terminal transferase-mediated dUTP nickend labeling (TUNEL) assay and by flow cytometric analysis for DNA content. Indeed, functional blockade of a v b 3 , similarly to the pharmacological MAPK inhibitor U0126, synergistically increased both the proportion of CYR61-overexpressing breast cancer cells in the G 2 phase of the cell cycle and the appearance of sub-G 1 hypodiploid (apoptotic) cells caused by Taxol. Strikingly, CYR61 overexpression impaired the accumulation of wild-type p53 following Taxol exposure, while inhibition of a v b 3 or ERK1/ERK2 MAPK signalings completely restored Taxol-induced upregulation of p53. Moreover, antisense downregulation of CYR61 expression abolished the anchorage-independent growth of breast cancer cells engineered to overexpress HRG, and significantly increased their sensitivity to Taxol. Our data provide evidence that CYR61 is sufficient to promote breast cancer cell proliferation, cell survival, and Taxol resistance through a a v b 3 -activated ERK1/ERK2 MAPK signaling. The identification of a 'CYR61-a v b 3 autocrine loop' in the epithelial compartment of breast carcinoma strongly suggests that targeting a v b 3 may simultaneously prevent breast cancer angiogenesis, growth, and chemo resistance.
The angiogenic inducer CYR61 is differentially overexpressed in breast cancer cells exhibiting high levels of Heregulin (HRG), a growth factor closely associated with a metastatic breast cancer phenotype. Here, we examined whether CYR61, independently of HRG, actively regulates breast cancer cell survival and chemosensitivity, and the pathways involved. Forced expression of CYR61 in HRG-negative MCF-7 cells notably upregulated the expression of its own integrin receptor a v b 3 (>200 times). Small peptidomimetic a v b 3 integrin antagonists dramatically decreased cell viability of CYR61-overexpressing MCF-7 cells, whereas control MCF-7/V remained insensitive. Mechanistically, functional blockade of a v b 3 specifically abolished CYR6-induced hyperactivation of ERK1/ERK2 MAPK, whereas the activation status of AKT did not decrease. Moreover, CYR61 overexpression rendered MCF-7 cells significantly resistant (>10-fold) to Taxol-induced cytotoxicity. Remarkably, a v b 3 inhibition converted the CYR61-induced Taxol-resistant phenotype into a hypersensitive one. Thus, the augmentation of Taxol-induced apoptotic cell death in the presence of a v b 3 antagonists demonstrated a strong synergism as verified by the terminal transferase-mediated dUTP nickend labeling (TUNEL) assay and by flow cytometric analysis for DNA content. Indeed, functional blockade of a v b 3 , similarly to the pharmacological MAPK inhibitor U0126, synergistically increased both the proportion of CYR61-overexpressing breast cancer cells in the G 2 phase of the cell cycle and the appearance of sub-G 1 hypodiploid (apoptotic) cells caused by Taxol. Strikingly, CYR61 overexpression impaired the accumulation of wild-type p53 following Taxol exposure, while inhibition of a v b 3 or ERK1/ERK2 MAPK signalings completely restored Taxol-induced upregulation of p53. Moreover, antisense downregulation of CYR61 expression abolished the anchorage-independent growth of breast cancer cells engineered to overexpress HRG, and significantly increased their sensitivity to Taxol. Our data provide evidence that CYR61 is sufficient to promote breast cancer cell proliferation, cell survival, and Taxol resistance through a a v b 3 -activated ERK1/ERK2 MAPK signaling. The identification of a 'CYR61-a v b 3 autocrine loop' in the epithelial compartment of breast carcinoma strongly suggests that targeting a v b 3 may simultaneously prevent breast cancer angiogenesis, growth, and chemo resistance.
Introduction
Increasing efforts have been devoted to characterize cellular proteins that play an active role in breast cancer progression. In this regard, we recently isolated and identified CYR61 (CCN1; the human homolog of a mouse immediate early response gene, Cyr61), an angiogenic regulator that is differentially expressed in invasive and metastatic human breast cancer cells (Tsai et al., 2000) . CYR61, a cysteine-rich, heparinbinding protein that is secreted and associated with the cell surface and the extracellular matrix (Yang and Lau, 1991) , belongs to the Cysteine-rich 61/Connective tissue growth factor/Nephroblastoma-overexpressed (CCN) gene family of angiogenic and growth regulators, which consists of CCN1 (CYR61), CCN2 (CTFG), CCN3 (NOV), CCN4 (WISP-1), CCN5 (WISP-2), and CCN6 (WISP-3) (Brigstock, 1999; Lau and Lam, 1999; Perbal, 2001; Brigstock et al., 2003; Planque and Perbal, 2003; Menendez et al., 2003; Perbal, 2004) . All CCN proteins, including CYR61, have been shown to mediate functions as diverse as cell proliferation, migration, adhesion, cell survival, differentiation, and extracellular matrix formation. Remarkably, CYR61 also regulates more complex processes, such as angiogenesis and tumorigenesis (Babic et al., 1998 (Babic et al., , 1999 Xie et al., 2001a; Tsai et al., 2002; Planque and Perbal, 2003) .
In the breast cancer scenario, we have previously shown that CYR61 is a downstream effector of Heregulin (HRG), a member of the epidermal growth factor (EGF)-like growth factor family closely involved in breast cancer progression and metastasis (Lupu et al., 1996; Tsai et al., 2000 Tsai et al., , 2003 Atlas et al., 2003; Menendez et al., 2003) Moreover, we established that forced expression of CYR61, in the absence of HRG and Her-2/neu (erbB-2) oncogene overexpression, is sufficient to promote acquisition of hormone independence and anti-estrogen resistance in human breast cancer cells (Tsai et al., 2002) . Indeed, CYR61 enhances a metastatic phenotype by promoting cell proliferation in soft agar, cell migration and invasion, and Matrigel outgrowth of breast cancer cells (Tsai et al., 2000 (Tsai et al., , 2002 . In our evaluation of CYR61 in breast tumor biopsies, a 40% of estrogen receptor (ER)-negative invasive breast carcinomas were found to express high levels of CYR61 protein (Tsai et al., 2000) . More recently, CYR61 overexpression was associated with advance stage, size, and lymph node involvement of primary breast tumors (Xie et al., 2001b) . Although these results strongly indicate that CYR61 may play a key role in the process of breast cancer progression and might serve as valuable tool for monitoring the tumor status, the ultimate molecular mechanisms by which CYR61 promotes an aggressive breast cancer phenotype are still largely unknown.
Depending on the biological context and cell model system, CYR61 is thought to act in an autocrineparacrine manner to promote cell growth, migration, and angiogenesis, through the interaction with its multiple integrin receptors (a v b 3 , a v b 5 , a IIb b 3 , and a 6 b 1 ; Kireeva et al., 1998; Jedsadayanmata et al., 1999; Chen et al., 2000; Grzeszkiewicz et al., 2001) . However, most of the CYR61-promoted effects are mediated via its direct binding with the integrin receptor a v b 3 , which has been implicated in the pathophysiology of malignant tumors. In addition to its expression on the surface of angiogenic endothelial cells, a v b 3 is also expressed on the surface of tumor cells in a variety of cancers. In breast cancer, a v b 3 characterizes the metastatic phenotype, and its expression is upregulated in invasive tumors and distant metastases (Gasparini et al., 1998; Meyer et al., 1998) . We recently postulated that CYR61-enhanced breast cancer progression may require a concomitant overexpression of a v b 3 (Tsai et al., 2000; Menendez et al., 2003) . Indeed, we observed that a v b 3 levels were significantly augmented in MCF-7 cells engineered to overexpress HRG when compared with control cells (Tsai et al., 2000) . In addition, we determined that functional blockade of a v b 3 using LM609, a monoclonal antibody which binds to a conformational epitope resulting from the post-translational association of the a v and b 3 integrin subunits, completely blocked the Matrigel outgrowth of HRG-overexpressing breast cancer cells (Tsai et al., 2000) . These results strongly suggested that a functional a v b 3 -dependent signaling is required for maintaining the invasive capacity of breast cancer cells overexpressing HRG. Moreover, it is reasonable to hypothesize that the aggressive phenotypes induced by HRG are mediated, in part if not entirely, through the interaction of CYR61 with its integrin receptor a v b 3 . Taken into account that the aggressiveness of a tumor depends, at least in part, on its ability to proliferate in a deregulated manner and its sensitivity to chemotherapy-induced cell damage, we here examined the effects of CYR61 overexpression in breast cancer cell survival and chemosensitivity, and the signaling pathways involved. Interestingly, our data provide evidence that CYR61 is sufficient to regulate breast cancer cell proliferation, cell survival, and chemosensitivity through its ability to strongly activate a a v b 3 -ERK1/ERK2 MAPK signaling. The identification of a previously unrecognized CYR61-triggered 'CYR61-a v b 3 autocrine loop' in the epithelial compartment of breast carcinoma strongly suggests that targeting a v b 3 may simultaneously prevent breast cancer angiogenesis, growth, and chemoresistance.
Results

CYR61 overexpression upregulates a v b 3 integrin in breast cancer cells
We envisioned that high levels of CYR61 would be a prerequisite for the high levels of a v b 3 integrin found in HRG-overexpressing breast cancer cells. To assess this hypothesis, we took advantage of a recent cellular model of breast cancer CYR61 overexpression developed in our laboratory, in which nontumorigenic and estrogendependent MCF-7 cells, which express very low to undetectable levels of CYR61, HRG, and erbB-2, were stably transfected with the full-length cDNA of CYR61 (Tsai et al., 2002) . To determine if overexpression of CYR61 in breast cancer cells altered the levels of its integrin receptor a v b 3 in the absence of HRG overexpression, the cell surface expression of a v b 3 in two representative CYR61 derivatives (MCF-7/C2-6 and MCF-7/C2-9 clones) was assessed by flow cytometry of cells stained with the anti-a v b 3 monoclonal antibody LM609. As control, the cells were stained with the appropriate antibody isotype. In MCF-7 breast cancer cells transfected with an empty vector (MCF-7/V), which expresses very low levels of CYR61, a v b 3 integrin was almost not detectable by flow cytometry (Figure 1a) . Interestingly, an equivalent flow cytometric analysis demonstrated a very significant increase of a v b 3 levels in CYR61-transfected MCF-7/C2-6 and MCF-7/C2-9 clones ( Figure 1a) .
To confirm the results obtained by flow cytometry we next analysed the impact of CYR61 overexpression in the subcellular localization of a v b 3 . To address this question, CYR61-overexpressing MCF-7/C2-6 and MCF-7/C2-9 clones and matched control MCF-7/V cells were permeabilized with Triton X-100 for the intracellular delivery of an anti-a v b 3 monoclonal antibody, and then the cellular pattern of a v b 3 was assessed by immunofluorescence microscopy. The membrane staining of a v b 3 was almost undetectable in MCF-7/V control cells (Figure 1b) . Conversely, CYR61-overexpressing MCF-7/C2-6 and MCF/C2-9 transfectants showed a prominent cell-surface staining of a v b 3 (Figure 1b) . In fact, a v b 3 integrin in CYR61-overexpressing MCF-7 cells was to some extent distributed throughout the cytoplasm. Although direct quantitative interpretation of immunofluorescence is not possible, comparison of the intensity of a v b 3 dots observed with the a v b 3 -specific antibody revealed an obvious and highly reproducible difference between CYR61 transfectants and control cells. Upregulation of a v b 3 by CYR61 overexpression was also evident when a v b 3 protein accumulation was monitored by immunoblotting (Figure 1c, top) . When the expression levels of a v b 3 integrin were quantitatively evaluated using an expression index (Geo Mean (GM) Fluoresence Â % of a v b 3 -positive cells-M1; Figure 1a ), this approach clearly demonstrated that CYR61 overexpression dramatically increased (>200 times) the basal level of a v b 3 expression in MCF-7 breast cancer cells (Figure 1c , bottom). CYR61 was highly expressed in the CYR61 transfectants as determined by Western blotting analysis using conditioned media concentrated from the C2-6 and C2-9 clones or a vector control clone (Figure 1c , top). Indeed, the expression level of CYR61 in MCF-7/C2-6 and MCF-7/C2-9 clones was comparable to that in MDA-MB-231 cells (an aggressive breast cancer cell line naturally overexpressing HRG and CYR61), as compared with the wild-type MCF-7 or MCF-7/V cells, in which CYR61 was nearly undetectable. This is the first indication showing that upregulation of a v b 3 integrin expression in human breast epithelial cells can be achieved solely by CYR61 overexpression, irrespective of HRG status. Importantly, the basal level of a v b 3 expression was significantly higher in MDA-MB-231 cells as compared with MCF-7 cells engineered to overexpress CYR61. Therefore, in breast cancer cells, integrin expression in CYR61 derivatives MCF-7/C2-6 and C2-9 clones, and matched control MCF-7/V cells. The specific surface expression of a v b 3 in CYR61-overexpressing MCF-7/C2-6 and C2-9 clones, and matched control MCF-7/V cells was determined by flow cytometry by measuring the binding of a mouse anti-a v b 3 antibody (clone LM609; Chemicon) as described in 'Materials and methods'. The data presented summarize the mean of the Geo Mean (GM) fluorescence parameter (7s.d.) from three independent experiments. (b) In situ immunofluorescent staining of a v b 3 integrin in CYR61 derivatives MCF-7/C2-6 and C2-9 clones, and matched control MCF-7/V cells. (c) Correlation between the expression of CYR61 and a v b 3 in breast cancer cells. Top: Subconfluent wild-type MCF-7, MCF-7/V, MCF-7/C2-9, MCF-7/C2-6, and MDA-MB-231 breast cancer cells were maintained in serum-free media for 48 h in 100-mm plates. The conditioned media were collected, concentrated 20 Â , resolved by 10% Tris-glycine SDS-PAGE, and assayed for CYR61 expression using a rabbit anti-CYR61 polyclonal antibody (ab2026; 1 : 2000 dilution). In all, 50 mg weight of whole-cell lysates from the same experimental 100-mm plate were resolved by 10% Tris-glycine SDS-PAGE, transferred to nitrocellulose membranes, and then probed with a mouse monoclonal anti-a v b 3 antibody (LM609 clone). Bottom: A a v b 3 expression index was calculated using the formula GM (Geo Mean Fluoresence) Â % of a v b 3 -positive cells. Data presented summarize the mean (columns)7s.d. (bars) of three independent experiments naturally overexpressing both HRG and CYR61 (i.e. MDA-MB-231 cells), it is likely that HRG further enhances CYR61-stimulated a v b 3 expression in a synergistic manner. We are currently investigating the ultimate mechanism responsible for the exacerbated levels of a v b 3 in MDA-MB-231 breast cancer cells.
CYR61 overexpression upregulates PI-3 0 K-AKT and MEK1/MEK2-ERK1/ERK2 signaling cascades in breast cancer cells
The CYR61-driven a v b 3 signaling network activates several signaling pathways leading to enhanced endothelial cell survival and proliferation (Grzeszkiewicz et al., 2001; Leu et al., 2002) . It has been previously shown that some of the phenotypic changes dictated by a v b 3 are dependent upon activation of phosphatidylinositol 3 0 -kinase (PI-3 0 K)/protein kinase B (AKT) and ERK1/ERK2 MAPK transduction cascades (King et al., 1997; Gilmore et al., 2000; Lee and Juliano, 2000; Zhang et al., 2002; Roberts et al., 2003) , which play a critical role in apoptosis and cell proliferation, respectively. Therefore, we examined whether the antiapoptotic PI-3 0 K/AKT cascade as well as the cell cycle regulatory ERK1/ERK2 MAPK signaling pathway were altered in CYR61-overexpressing MCF-7 breast cancer cells. While downstream of PI-3 0 K, the content of total AKT was similar in CYR61-overexpressing and control MCF-7/V cells, active AKT (P-AKT Ser473 ) was significantly higher in CYR61 derivatives MCF-7/C2-6 and MCF-7/C2-9 (Figure 2 , left panel). On the other hand, the content of total MAPK was similar in CYR61-overexpressing and control MCF-7/V cells, whereas the activation status of ERK1/ERK2 MAPK, as monitored by immunoblotting using polyclonal antibodies recognizing the activated form of the ERK1 and ERK2 enzymes (P-ERK1/ERK2 MAPK), was significantly higher in MCF-7/C2-6 and MCF-7/C2-9 transfectants in comparison to matched control MCF-7/ V cells (Figure 2 , left panel). LY294002, a specific inhibitor of the p110 catalytic subunit of PI-3 0 K, particularly affected PI-3 0 K/AKT signaling as indicated by the complete inhibition of P-AKT Ser473 . As previously demonstrated by Zimmermann and Moelling (1999) in MCF-7 breast cancer cells, a very significant activation of ERK1/ERK2 was promoted by LY294002-induced inhibition of PI-3 0 K and AKT in MCF-7/V control cells, thus evidencing an active crosstalk between the Raf-MEK-ERK and the PI-3 0 K-AKT pathways. Interestingly, inhibition of AKT activation by LY294002 slightly altered the hyperactivation status of ERK1/ ERK2 MAPK in CYR61-derivatives MCF-7/C2-6 and MCF-7/C2-9 (Figure 2 , right panel). U0126, a noncompetitive inhibitor of the dual specificity MAPK kinases MEK1 and MEK2, the enzymes that activate MAPK, completely eliminated P-MAPK without affecting active AKT (Figure 2 
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Figure 2 CYR61 overexpression activates PI-3 0 K-AKT and MEK1/MEK2-ERK1/ERK2 signaling cascades in MCF-7 breast cancer cells. Left: Total and activated (phosphorylated) AKT and ERK1/ERK2 MAPK protein levels in CYR61-overexpressing MCF-7/C2-6 and MCF-7/C2-9 and matched control MCF-7/V cells. Overnight serum-starved cells at 75-80% confluence were washed two times with PBS, lysed in buffer, subjected to electrophoresis on 10% SDS-PAGE, and transferred to nitrocellulose membranes. Immnunoblots with anti-AKT, anti-P-AKT, anti-ERK1/ERK2 MAPK, and anti-P-ERK1/ERK2 MAPK show equivalent amounts of the proteins in each extract (25 mg). Blots were reprobed with an antibody for b-actin to control for protein loading and transfer. Results are representative of three independent experiments. Right: Overnight serum-starved cells at 75-80% confluence were treated for 2 h with vehicle (v/v), LY294002 (40 mM), U0126 (20 mM), or both LY294002 and U0126. Total protein (25 mg) was resolved by SDS-PAGE and subjected to immunoblot analyses for AKT, P-AKT, ERK1/ERK2 MAPK, and P-ERK1/ERK2 MAPK as described above. Blots were reprobed with an antibody for b-actin to control for protein loading and transfer. Results are representative of three independent experiments the inhibitors. These results strongly indicate that, downstream of a v b 3 , CYR61 overexpression concomitantly activates PI-3 0 K-AKT and MEK1/MEK2-ERK1/ERK2 signaling cascades in breast cancer cells. These findings not only support earlier studies evidencing the ability of CYR61 to strongly activate AKT in other cellular systems Xie et al., 2004) , but suggest further that CYR61 overexpression may molecularly disrupt the crosstalk between these two signaling cascades at the level of Raf and AKT as the inhibition of PI-3 0 K does not lead to activation of the Raf-MEK-ERK cascade in CYR61-overexpressing MCF-7/C2-6 and MCF-7/C2-9 clones. a v b 3 signaling mediates cell survival and proliferation in CYR61-overexpressing breast cancer cells
We next evaluated whether cell survival and proliferation in MCF-7 cells engineered to overexpress CYR61 was associated with an increased signaling through CYR61 integrin receptor a v b 3 . To evaluate this issue, we examined the metabolic effects of a novel group of small peptidomimetic antagonists of a v b 3 (SC56631, SC68448, S-247, S-197, and S-205; Oncology Pharmacology, Discovery Research, Pharmacia Corporation, St Louis, MO, USA) towards CYR61 transfectants and control MCF-7/V cells. Table 1 provides the potency (IC 50 value) of these antagonists against human placentaderived a v b 3 or human platelet-derived a IIb b 3 , the two known b 3 integrins. Figure 3 shows the dose-dependent effects of SC56631, SC68448, S-247, S-197, and S-205 on the metabolic status of CYR61-overexpressing MCF-7/ C2-6 and MCF-7/C2-9 clones and MCF-7/V control cells as judged by the mitochondrial conversion of the tetrazolium salt, MTT, to its formazan product (MTT assay). A marked decrease in cell viability was observed in CYR61-and a v b 3 -overexpressing MCF-7/C2-6 and MCF-7/C2-9 clones cultured in the presence of SC68448, S-247, and S-196 . When the efficacy of a v b 3 antagonists was evaluated by calculating the IC 30 and IC 50 values (the dose of agents producing a 30 and 50% reduction in cell viability, respectively), we observed that CYR61-overexpressing MCF-7/C2-6 and MCF-7/C2-9 clones were exquisitely sensitive to S-247, the most potent and selective a v b 3 antagonist, with IC 50 values lower than 3 mM (Table 2) . Conversely, CYR61-and a v b 3 -negative MCF-7/V cells did not display signs of cytotoxicity even at S-247 concentrations as high as 10 mM. Of interest, CYR61-overexpressing MCF-7/C2-6 and MCF-7/C2-6 were insensitive to very high concentrations of S-205, a highly potent and selective antagonist of the b 3 integrin a IIb b 3 , further demonstrating the specificity of the molecular target (i.e. a v b 3 ) through which these a v b 3 antagonists promote cytotoxicity towards breast cancer cells. When the cell growth was measured by counting the cells after a 48 h treatment with a v b 3 integrin antagonists, a dosedependent inhibitory effect on cell proliferation as well as cell adhesion was observed in CYR61-overexpressing MCF-7/C2-6 and MCF-7/C2-9 clones treated with SC68448, S-247, or S-197. Of note, at SC68448, S-247, and S-196 concentrations higher than 1 mM, the cells were rounded and assembled in clusters either floating in the medium or weakly adherent on the culture support, whereas in the presence of S-205, the peptidomimetic agonist with the lowest affinity to a v b 3 , they formed a typical epithelioid monolayer (data not shown). These results, altogether, demonstrate that an active a v b 3 signaling is necessary to maintain cell viability in CYR61-overexpressing breast cancer cells.
CYR61 overexpression induces breast cancer cell resistance to paclitaxel (Taxolt)
Integrin signals are involved in diverse biological responses, including angiogenesis and tumor progression as well as in a variety of cellular activities, including cell migration, proliferation, and survival. Of interest, integrin signaling has recently been shown to modulate cancer cell responses to chemotherapeutic agents (Aoudjit and Vuori, 2001 ). This integrin-dependent phenomenon of innate chemoresistance has been termed cell adhesion-mediated drug resistance (Damiano et al., 1999; Gilmore et al., 2000) . Here, we evaluated whether CYR61-induced upregulation of a v b 3 would modulate breast cancer cell response to paclitaxel (Taxolt), an antimitotic drug commonly used in the treatment of advanced or metastatic breast cancer (Hortobagyi et al., 1997; Perez, 1998; Wiseman and Spencer, 1998) . Using the MTT assay, which is a crude measure of cell viability, we observed that CYR61-overexpressing MCF-7/C2-6 and MCF-7/C2-9 clones were between nine-and 12-fold more resistant to Taxol-induced cytotoxicity when compared with matched control MCF-7/V cells ( Figure 4a ).
We speculated that the reduced sensitivity to Taxol seen in CYR61-overexpressing MCF-7 cells was not simply the result of changes in cell proliferation, but might actually be due to a CYR61-promoted decrease in apoptotic cell death following Taxol-induced cell damage. To address this question, cells were exposed to 10 nM Taxol, cell death was measured by an ELISA that detects DNA-histone fragmentation, and the x-fold increase in apoptosis-related cell death was calculated by comparing the ELISA optical density readings of treated samples, with the values of the untreated cells as 1.0. Likewise, CYR61-overexpressing MCF-7/C2-6 and MCF-7/C2-9 clones treated with Taxol exhibited a negligible degree of cell death compared with that observed in control MCF-7/V cells ( Figure 4b ). Since soft-agar colony formation of cancer cells is thought to be one of the best in vitro correlates of the ability of cancer cells to grow in vivo, CYR61-overexpressing MCF-7 transfectants and MCF-7/V control cells were further analysed for their anchorage-independent growth properties in the presence of Taxol. Very low concentrations of Taxol (o10 nM) dramatically suppressed colony formation of empty-vector control cells growing in semisolid agar. In contrast, significant higher concentrations of Taxol (>50 nM) were required to inhibit the anchorage-independent soft agar clonogenic growth of CYR61-overexpressing MCF-7/C2-6 and MCF-7/C2-6 clones ( Figure 4c ). Thus, under anchorage-independent growth conditions, CYR61 overexpression increased between 5 and 10 times breast cancer cell resistance to Taxol. Altogether, these findings support the recent observations by Lin et al. (2004) suggesting that CYR61 plays an important role in resistance to chemotherapeutic agent-induced apoptosis and clearly demonstrate that CYR61 overexpression dramatically decreases the cytotoxic activity of Taxol towards breast cancer cells.
Functional blockade of a v b 3 reverses CYR61-induced breast cancer cell resistance to Taxol-induced cytotoxicity
To investigate whether CYR61-induced resistance to Taxol was specifically mediated through a v b 3 , CYR61-overexpressing and matched control cells were treated with Taxol in the absence or presence of a v b 3 antagonists. The effects of coexposure to suboptimal doses (lower than the IC 50 ) of SC68448, S-196, and S-247 on the response of CYR61-overexpressing MCF-7 cells to Taxol are shown in Table 3 . In order to measure the increase in Taxol sensitivity, a 'sensitization factor' was determined by dividing Taxol IC 50 values in the absence of a v b 3 antagonists by those in their presence. SC68448, S-196, and S-247 enhanced the cytotoxic activity of Taxol in a dose-dependent manner. Thus, as the concentration of a v b 3 antagonists increased, the efficacy of Taxol was significantly increased. Importantly, the sensitization effects were dependent on the ability of the peptidomimetic antagonists to specifically interact with a v b 3 . Thus, CYR61-overexpressing MCF-7/C2-6 and MCF-7/C2-9 clones incubated in the presence of 0.5 mM SC68448 (the a v b 3 antagonist with the lowest affinity and specificity for a v b 3 ) showed a 5-9-fold increase in Taxol sensitivity, while the addition of S-247 (the a v b 3 antagonist with the highest affinity and specificity for a v b 3 ) spectacularly increased Taxolinduced cytotoxicity up to 80 times. In agreement with the ability of the peptidomimetic antagonists to specifically work through its a v b 3 target, there was no significant enhancement of Taxol-induced cytotoxicity when a v b 3 -negative MCF-7/V cells were coexposed to SC68448, , and S-247 as single agents significantly decreased cell viability of CYR61-overexpressing MCF-7 cells at the concentrations examined. This indicated the presence of a potentially significant synergic/antagonist component. Thus, possible synergistic interactions between a v b 3 antagonists and Taxol could not be accurately discriminated from additive or antagonistic effects in the basis of the above data alone. Although there is still controversy over which method is best for detecting true in vitro synergy between drug combinations, we performed a series of isobologram transformations of multiple dose-response analyses (Berenbaum, 1989) . Representative transformations are presented graphically (isobolograms) in Figure 5a . The dashed line drawn between the IC 50 value for each a v b 3 antagonist alone and the IC 50 for Taxol alone indicates the alignment of theoretical isoeffect data points for additive interactions between a v b 3 antagonists and Taxol. The true IC 50 points (the experimental concentrations of a v b 3 antagonists and Taxol which combinedly produced 50% reduction in cell survival) were plotted and compared with the additive line. Data points above the dashed diagonal line of the additive effects in the isobole suggest antagonism and those below the diagonal suggest synergism. While these figures provide a graphical representation of a v b 3 antagonists-Taxol interactions, the values of the mean combination index (CI) for a particular cell line, drug combination, and effect level are also labeled. In addition, Student t tests were computed to evaluate whether significant differences in the CI means values occurred as compared to a null hypothesized CI of 1 (additivity) and to formally evaluate whether antagonism or synergism was evident. At the 50% effect level, concurrent administration of a v b 3 antagonists and Taxol resulted in a strong synergism (CI s o0.3) in CYR61-overexpressing MCF-7 C2-6 and MCF-7/C2-9 clones. In other words, the amount of the two agents together necessary to reduce MCF-7/C2-6 and MCF-7/C2-9 cell viability by 50% was only B0.2 times as much as would be required if they demonstrated purely additive behavior (Po0.001 versus a null hypothesized interaction index of 1 -additivity). The above results imply that CYR61 regulates breast cancer cell sensitivity to chemotherapeutic agents such as Taxol mainly through its interaction with the a v b 3 integrin, and that therapies depriving CYR61-overexpressing breast cancer cells of their a v b 3 proliferative signaling dramatically increase Taxol killing.
We also examined whether, downstream of a v b 3 , inhibition of PI-3 0 K-AKT or MEK1/MEK2-ERK1/ ERK2 pathways altered the cytoprotective actions of CYR61 overexpression in MCF-7 cells. To link CYR61-induced activation of PI-3 0 K or MAPK cascades to Taxol resistance, we used nontoxic concentrations of LY294002 and U0126, specific inhibitors of PI-3 0 K and of MEK1/MEK2 enzymatic activities, respectively. After coexposure to 20 mM LY294002, CYR61-overexpressing MCF-7/C2-6 and MCF-7/C2-9 clones showed up to 12-fold increase in sensitivity to Taxol. The cotreatment with 10 mM of the MEK inhibitor U0126 enhanced up to eightfold Taxol-induced cytotoxicity in CYR61-overexpressing MCF-7 cells (Table 3) . Conversely, unchanged Taxol IC 50 values were observed for matched control MCF-7/V cells in the presence of LY294002 or U0126. These results strongly suggest that, downstream of a v b 3 , CYR61-induced activation of PI-3 0 K-AKT or MEK1/MEK2-ERK1/ERK2 transduction cascades actively contribute to CYR61-promoted breast cancer cell resistance to Taxol.
Functional blockade of a v b 3 synergistically enhances Taxol-induced apoptosis in CYR61-overexpressing breast cancer cells
Since apoptosis is the predominant mechanism of cytotoxicity induced by chemotherapeutic agents, we analysed whether the failure of CYR61-overexpressing MCF-7 cells to activate apoptosis may account for CYR61-promoted resistance to Taxol. In addition, we evaluated the possibility that the synergistic decrease in cell viability of CYR61-overexpressing MCF-7 breast cancer cells cotreated with a v b 3 antagonists and Taxol would represent an enhancement of Taxol-induced apoptotic cell death. In these experiments, we employed the lowest clinically relevant concentration of Taxol (i.e. 10 nM) that blocks normal cell cycle progression at the G 2 -M of the cell cycle and induces ERK1/ERK2 MAPK activation (Torres and Horwitz, 1998; MacKeigan et al., 2000 MacKeigan et al., , 2002 . To evaluate Taxol-related apoptosis, we used a fluorometric terminal transferasemediated dUTP nick-end labeling (TUNEL) assay, which measure the fragmented DNA of apoptotic cells by catalytically incorporating fluorescein-12-dUTP at Taxol-induced cytotoxicity in the absence or presence of a v b 3 integrin antagonists SC68448, S-196, and S-247; MEK1/MEK2 blocker U0126; or PI-3 0 K inhibitor LY294002 was determined using a modified MTT reduction assay as described in 'Materials and methods'. Agents were studied in combination concurrently and were not renewed during the entire period of cell exposure. The degree of sensitization to Taxol by a v b 3 integrin antagonists, U0126 and LY294002 (values in parentheses), was evaluated by dividing IC 50 values of control cells (absence of a v b 3 integrin antagonists, U0126 or LY294002) by those obtained when cells were exposed to a v b 3 antagonists, U0126, or LY294002 during exposure to Taxol. a Resistance to Taxol-induced cytotoxicity was expressed as a x-fold factor by dividing IC 50 values in CYR61-overexpressing MCF-7/C2-6 and MCF-7/C2-9 clones by that found in MCF-7/V-matched control cells 3 0 -OH DNA ends using the enzyme terminal deoxynucleotidyl transferase (TdT). In our experiments, fluorescein-12-dUTP-labeled DNA in Taxol-treated cells was visualized directly by fluorescence microscopy. With this protocol, Taxol by itself was found to induce a significant increase in basal apoptosis (e.g. versus untreated cells) in CYR61-negative MCF-7/V cells (Figure 5b, top panels) . Conversely, the CYR61 derivative MCF-7/C2-6 did not undergo major apoptosis after Taxol exposure as assessed by TUNEL labeling (Figure 5b apoptosis, we recently observed that S-247 significantly reduces S phase cell subpopulation without promoting apoptotic cell death of HRG-and CYR61-overexpressing MDA-MB-231 breast cancer cells (Vellon et al., 2004) . These results, altogether, strongly suggest that a v b 3 antagonists such as S-247 may specifically regulate breast cancer cell cycle progression without affecting breast cancer cell death. Interestingly, while the concurrent administration of S-247 and Taxol exerted little effects on Taxol-mediated apoptosis in CYR61-negative MCF-7/V cells, a significant enhancement of Taxolinduced apoptosis towards CYR61-overexpressing MCF-7/C2-6 cells was detected in the presence of the a v b 3 antagonist S-247 (Figure 5b, bottom panels) . Indeed, the combination treatment in MCF-7/C2-6 cells produced an B3-fold enhancement of apoptosis over the expected additive effect. This trend was also observed following coexposure of CYR61 transfectants to Taxol and a v b 3 antagonists SC68448 and S-196 (data not shown). Therefore, it is tempting to postulate that CYR61 overexpression in breast cancer cells may drive breast cancer cell survival and chemoresistance by emitting a proliferative and/or survival input via the integrin receptor a v b 3 , which might integrate signals from CYR61 to proliferative and/or antiapoptotic signaling pathways. (Figure 6a ). These results demonstrate that a v b 3 antagonists such as S-247 and S-196 specifically block the CYR61-triggered 'CYR61-a v b 3 autocrine loop' by inactivating the MEK1/ MEK2-ERK1/ERK2 signaling cascade without affecting the antiapoptotic activity of AKT. Taxol binds to b-tubulin, stabilizes the microtubule, prevents its depolymerization, leads to arrest of cells in G 2 -M and ultimately, triggers apoptosis (Schiff et al., 1979; Parness and Horwitz, 1981; Blagosklonny et al., 1995 Blagosklonny et al., , 1996 Blagosklonny and Fojo, 1999) . Interestingly, Taxol also induces the activation of the Raf-MEK-ERK pathway, which is considered a proliferation and cell survival pathway (Blagosklonny et al., 1995; McDaid and Horwitz, 2001; Seidman et al., 2001) . Accordingly, it has been shown that inhibition of MEK combined with Taxol induces a dramatic enhancement of apoptosis in various tumor cell lines (MacKeigan et al., 2000 (MacKeigan et al., , 2002 McDaid and Horwitz, 2001; Seidman et al., 2001; Yu et al., 2001) . Considering the ability of a v b 3 antagonists to specifically block ERK1/ERK2 MAPK hyperactivation in CYR61-overexpressing breast cancer cells, we reasoned that a functional blockade of a v b 3 integrin may mimic the enhancing effects of pharmacological blockers of MEK on Taxol-induced apoptotic cell death. To examine the mechanism of enhanced apoptosis observed with Taxol and a v b 3 antagonists, their effects on cell cycle progression were studied in parallel to those induced by the pharmacological MERK/ERK inhibitor U0126 (Figure 6b ; Table 4 ). First, the CYR61-overexpressing MCF-7/C2-9 clone was treated with Taxol, S-247, and U0126 as single agents. As expected, U0126-induced inhibition of ERK1/ERK2 activity arrested cells in G 1 , while 45 nM Taxol (the IC 50 value for MCF-7/C2-9 cells) produced a significant G 2 -M block. In total, 13% of the cells underwent apoptosis in the presence of Taxol, whereas a negligible increase in cell death was detected in the presence of U0126 when compared with the untreated controls. As previously reported by MacKeigan et al. (2000) , the combination of Taxol and U0126 substantially increased cell death as evidenced by accumulation of a sub-G 1 population that has o2 N DNA and represents dead cells. In addition, a significant increase in the percentage of cells in G 2 -M was observed when MCF-7/C2-9 cells were concurrently treated with U0126 and Taxol. Similarly to U0126, a suboptimal concentration of the a v b 3 antagonist S-247 (0.25 mM) caused little apoptosis (8% compared with 5% in untreated control cells), while it significantly decreased S phase cell subpopulation from 31 to 13%. A more dramatic reduction in the S phase proliferating fraction of MCF-7/C2-9 cells (up to 75% reduction at 1 mM S-247) with a modest increase in sub-G 1 apoptotic cells was observed in the presence of higher concentrations of S-247 (data not shown). Remarkably, there was a synergistic increase in the proportion of sub-G 1 cells (up to 27%), while the percentage of Taxol-treated MCF-7/ C2-9 cells in G 2 -M dramatically increased from 30 to 57% following coexposure to S-247 (Figure 6b ; Table 4 ). These results not only confirm that a v b 3 antagonists such as S-247 specifically regulate cell cycle progression without affecting apoptotic cell death but also further demonstrate that functional blockade of a v b 3 signaling in CYR61-overexpressing breast cancer cells mimics the molecular effects of MEK1/MEK2 inhibitors by synergistically promoting both the proportion of cells in the G 2 -M phase of the cell cycle and the appearance of sub-G 1 hypodiploid cells caused by Taxol (Figure 6c ).
CYR61-a v b 3 loop modulates Taxol-induced accumulation of p53 through the MEK1/MEK2-ERK1/ERK2 MAPK cascade
Data accumulated in recent years have shown that Taxol can activate a number of signal transduction pathways implicated in different, often opposite, cell activities such as proliferation, differentiation, stress response, and apoptosis. Thus, it has been shown that Taxol-induced apoptosis involves a dose-and timedependent accumulation of the tumor suppressor protein p53 (Blagosklonny et al., 1995; Giannakakau et al., 2001) . Here, we evaluated the effects of Taxol on p53 expression and ERK1/ERK2 activity in CYR61-overexpressing and matched control MCF-7/V cells. As expected, a dramatic dose-dependent increase of p53 expression was observed in MCF-7/V control cells after 24 h exposure to increasing concentrations of Taxol (up to 100 nM). Interestingly, CYR61-overexpressing MCF-7 cells showed a markedly reduced ability to upregulate p53 expression in response to Taxol (Figure 7 , left panels). In agreement with previous studies, basal ERK1 and ERK2 activities in MCF-7/V cells were notably enhanced by treatment with nanomolar doses of Taxol, whereas high endogenous activity of ERK1/ERK2 (Figure 7 , right panels). Based on these results, we decided to study whether the functional blockade of a v b 3 would restore the ability of Taxol to upregulate p53 in CYR61-overexpressing breast cancer cells in an ERK1/ ERK2 MAPK-related manner. Remarkably, coadding a v b 3 integrin antagonist S-247 for 24 h elicited a Taxolinduced upregulation of p53 in CYR61-overexpressing MCF-7 cells comparable to that found in matched control cells (Figure 7, right panels) . Moreover, this effect was concurrent with a complete inactivation of ERK1/ERK2 MAPK. Similarly, MEK inhibitor U0126 completely blocked ERK1/ERK2 activation by Taxol in CYR61 transfectants, and restored the ability of CYR61-overexpressing MCF-7 cells to upregulate p53 following Taxol exposure. Conversely, pharmacological inhibition of MEK1/MEK2-ERK1/ERK2 cascade by U0126 significantly reduced Taxol-induced activation of p53 in matched control MCF-7/V cells, in agreement with earlier studies demonstrating that the ability of Taxol to both induce wild-type p53 in MCF-7 cells and activate ERK1/ERK2 requires a functional Raf-MEK1/ MEK2-ERK1/ERK2 cascade (Blagosklonny et al., 1995) . Taken together, these findings suggest that CYR61 could suppress Taxol-induced apoptosis in an a v b 3 -ERK1/ERK2 MAPK dependent manner. Intriguingly, CYR61, also through its integrin receptor a v b 3 , seems to inhibit the function of wild-type p53 following Taxol-induced cell damage. We are currently investigating whether CYR61-activated a v b 3 -ERK1/ERK2 MAPK signaling may contribute to the lack of functional p53 by modulating either protein stability and/or cellular localization of p53 in CYR61-overexpressing MCF-7 cells.
Blockade of CYR61 expression decreases cell survival and chemoresistance in HRG-overexpressing breast cancer cells
In a final scenario, we characterized breast cancer cell survival and chemosensitivity following blockade of CYR61 expression in MCF-7 cells engineered to overexpress HRG (MCF-7/T7 cells). When the conditioned media from T7/CYR61-AS4 and T7/CYR61-AS7 clones were collected and the expression levels of CYR61 were determined by Western blotting, very low levels of CYR61 were observed when compared to those found in HRG-overexpressing MCF-7/T7 cells (Figure 8a ). In addition, blockade of CYR61 expression in MCF-7 cells engineered to overexpress HRG was able to reduce a v b 3 Table 4 Cell cycle percentages for CYR61-overexpressing MCF-7/ C2-9 cells treated with Taxol, U0126, S-247, and their combinations Control  5  56  32  12  Taxol  13  28  42  30  U0126  6  79  13  8  S-247  7  60  24  16  Taxol+U0126  24  37  20  43  Taxol+S-247  27  12  31  57 Untreated MCF-7/C2-9 cells and MCF-7/C2-9 cells treated with Taxol in the absence or presence of U0126 or S-247 for 24 h were fixed, stained with propidium iodide, and analysed for DNA content by flow cytometry. The percentage of cells in each cell cycle phase is shown. Standard deviation in each experimental condition was less than 1% after three independent experiments β-actin were unchanged in antisense-CYR61 transfectants when compared with those found in T7 and T7/AC-V controls (Figure 8a ). Thus, this cellular system exhibits an intact HRG-Her-2/neu signaling in the absence of CYR61 overexpression. Since the colony-forming assay in soft agar measures both anchorage-independent proliferation and cell survival, we next focused on an active role of CYR61 on HRG-enhanced breast cancer cell survival. Indeed, the acquisition of anchorageindependent growth is generally considered to be one of the in vitro properties associated with the malignancy of cells, and colonization of metastatic tumor cells at a distant site may be partially modeled in soft agar assays. More importantly, it is well established that MCF-7 cells are not anchorage-independent in the absence of estradiol (E 2 ). Colony formation of MCF-7 cells in soft agar observed, if any, represent the background level for the colony formation assay. MCF-7, MCF-7/T7, T7/CYR61-AS4, and T7/CYR61-AS7 cells were cultured in E 2 -depleted media and assayed in a soft-agar assay in the absence of E 2 , using phenol red-free medium containing 10% charcoal-stripped calf serum. The cells were allowed to form colonies for 2 weeks and were counted using a colony counter. As expected, MCF-7 cells did not form colonies in the absence of E 2 . Interestingly, E 2 -independent soft agar colony formation of HRG-overexpressing MCF-7/T7 cells was drastically reduced in the absence of high levels of CYR61 expression. Thus, T7/CYR61-AS4 and T7/CYR61-AS7 clones were almost unable to grow in an anchorage-independent manner (Figure 8a and b) . Moreover, downregulation of CYR61 expression in HRG-overexpressing T7 cells significantly decreased HRG-promoted resistance to Taxol (Figure 8c ). -independent breast cancer cell growth in anchorageindependent conditions, whereas it does not modify the activation status of Her-2/neu. Top panel: Overnight serum-starved cells at 75-80% confluence were harvested in lysis buffer, 40 mg of total protein was resolved by 3-8% Tris-Acetate NuPAGE, and subjected to immunoblot analyses for P-p185 HerÀ2/neu using a Her-2/neu phosphorylation state-specific antibody (clone PN2A). Middle panel: Softagar (anchorage-independent) colony formation assays upon E 2 -depleted conditions for MCF-7, MCF-7/V, MCF-7/T, MCF-7/T7 CYR61 AS-4, and MCF-7/T7 CYR61 AS-7 cells. The data presented are mean of number of colonies (columns)7s.d. (bars). All assays were performed at least three times in triplicate. Bottom panel: CYR61 protein levels in the conditioned media were analysed by Western blotting as described in Figure 1c. (b) Microphotographs of representative soft agar assays are shown (150-fold magnification). (c) Downregulation of CYR61 expression reduces HRG-enhanced breast cancer cell resistance to Taxol-induced cytotoxicity. Taxol sensitivity in HRG-overexpressing MCF-7/T7 cells and their CYR61 antisense derivatives was determined using a standard colorimetric MTT reduction assay as described above. Data presented summarize the mean (7s.d.) of three independent experiments made in triplicate loop is necessary for the maintenance of HRG-enhanced cell survival and chemoresistance in breast cancer cells.
Discussion
Our early studies demonstrated that CYR61, an angiogenic factor that acts as a downstream effector of HRG-induced metastatic phenotype, is overexpressed in breast cancers and is actively involved in the acquisition of an estrogen-independent breast cancer phenotype (Tsai et al., 2000 (Tsai et al., , 2002 . CYR61 was found to be expressed at high levels in HRG-overexpressing invasive breast cancer cell lines and metastatic breast cancers, whereas expression of CYR61 was undetectable in either normal breast cancer cell lines or normal breast tissue (Tsai et al., 2000; Sampath et al., 2001) . Moreover, forced expression of CYR61 in MCF-7 cells significantly enhanced their anchorage-independent cell growth in soft agar and profoundly stimulated their ability to form large tumors in nude mice (Xie et al., 2001a; Tsai et al., 2002) . These findings motivated us to investigate the ultimate molecular mechanisms through which CYR61 overexpression, independently of HRG, may promote breast cancer aggressiveness. We have previously shown that the functional a v b 3 integrin is required for maintaining the invasive capacity of HRG-expressing cells and that the aggressive phenotypes induced by HRG are mediated, in part if not entirely, by CYR61 and its receptor a v b 3 integrin (Tsai et al., 2000) . Here, we further demonstrate that overexpression of CYR61 in MCF-7 cells is sufficient to dramatically increase the expression levels of its integrin receptor a v b 3 , which is known to correlate with the aggressiveness of the breast cancer disease (Gasparini et al., 1998) . Furthermore, functional blockade of a v b 3 integrin induces a specific cytotoxic effect towards breast cancer cells engineered to overexpress CYR61, while the specific downregulation of CYR61 expression concomitantly reduces both a v b 3 expression and HRG-enhanced breast cancer cell survival. To our best knowledge, this is the first report showing that CYR61 can promote breast cancer cell proliferation and survival through the upregulation of its own integrin receptor a v b 3 , thus generating a CYR61-primed CYR61-a v b 3 autocrine loop. Interestingly, Xie et al. (2004) recently reported that CYR61 overexpression in glioma cells led to the upregulation of distinct integrins. Altogether, these findings strongly suggest that a prometastatic CYR61-a v b 3 autocrine loop may occur in a variety of cancers.
Another important finding of this study is the characterization of CYR61 and a v b as a survival loop protecting human breast cancer cells from cell damage following exposure to Taxol, an antimitotic drug commonly used in the treatment of advanced or metastatic breast cancer. Overexpression and activation of Her-2/neu-coded p185 HerÀ2/neu oncoprotein, an HRGtransactivated orphan receptor, is the major mechanism through which human breast cancer cells acquire resistance to taxanes such as Taxol (Yu et al., 1996 (Yu et al., , 1998 Yu and Hung, 2000; Yu, 2001) . Remarkably, our current results reveal that CYR61 can regulate breast cancer cell sensitivity to Taxol-induced cell damage independently of Her-2/neu overexpression and/or HRG-induced Her-2/neu transactivation. During the preparation of this manuscript, Lin et al. (2004) showed that CYR61 overexpression significantly activates AKT and concurrently confers resistance to Taxol-induced apoptosis in breast cancer cells. Since the inhibition of a v b 3 using the monoclonal antibody LM609 prevented this phenotype, the authors suggested that CYR61 can promote breast cancer cell chemoresistance through activation of an a v b 3 -PI-3 0 K-AKT signaling pathway. Although in our model system CYR61 overexpression was found to significantly activate AKT, incubation of CYR61-overexpressing breast cancer cells with small peptidomimetic antagonists of a v b 3 did not decrease the phosphorylation of AKT. In agreement with our findings, Reinmuth et al. (2003) recently demonstrated that the a v b 3 integrin antagonist S-247 was unable to modulate the activation status of AKT in human umbilical vein endothelial cells (HUVECs). Considering that the specific inhibitor of the p110 catalytic subunit of PI-3 0 K LY294002 suppressed AKT activation and significantly enhanced Taxol killing in CYR61-overexpressing MCF-7 cells, small peptidomimetic antagonists of a v b 3 such as S-247 are likely to inhibit a v b 3 -driven cellular signaling independently of AKT. For instance, the integrin-mediated activation of Ras has been implicated in preventing anoikis in a manner that is independent of PI-3 0 K, the main upstream activator of AKT (Rosen et al., 2000) . In this regard, functional blockade of a v b 3 using cell growth inhibitory concentrations of a v b 3 integrin antagonists completely prevented ERK1/ERK2 MAPK hyperactivation and concurrently sensitized, in a synergistic manner, CYR61-overexpressing breast cancer cells to Taxol-induced cell death. Considering that a v b 3 antagonists such as S-247, when used as single agent, showed no apoptotic activity but rather suppressed the S phase cell subpopulation towards CYR61-and HRG-overexpressing breast cancer cells (Vellon et al., 2004) , and that the MEK inhibitor U0126 was found to mimic the effects of a v b 3 antagonists on both cell cycle progression and sensitization to Taxol-induced apoptosis and G 2 -M blockade in CYR61-overexpressing breast cancer cells, it is reasonable to suggest that peptidomimetic a v b 3 integrin antagonists may modulate Taxol efficacy through specific inhibition of proliferative cascades such as Ras-Raf-ERK1/ERK2 MAPK, without affecting antiapoptotic signalings such as PI-3 0 K/AKT. These results, however, do not exclude the possibility that CYR61 overexpression upregulates AKT in a a v b 3 -dependent manner. Remarkably, Xie et al. (2004) demonstrated that CYR61, concurrently with its ability to upregulate a v b 3 in glioma cells, significantly activated, in a PI-3 0 Kdependent manner, the integrin-linked kinase (ILK). ILK can interact directly with the cytoplasmic domain of the b 3 integrin subunit and phosphorylate directly the serine 473 of AKT (Radeva et al., 1997; Novak et al., 1998; Yoganathan et al., 2000) . Taking into consideration that the small peptidomimetic a v b 3 antagonists used in this study selectively distinguish between the two known b 3 integrins (a v b 3 and a IIb b 3 ), it is likely that these compounds preferentially block a v -driven signaling in the a v b 3 heterodimer, thus unaffecting b 3 -dependent molecular effectors such as PI-3 0 K and ILK. Nevertheless, we are currently investigating whether a crosssignaling between CYR61, a v b 3, ILK, and AKT is occurring in breast cancer cells, and whether anti-a v b 3 therapies based on either monoclonal antibody (i.e. LM609) or small peptidomimetic antagonists (i.e. S-247) differentially modulate downstream transduction cascades in a v b 3 -overexpressing breast cancer cells. Interestingly, a v integrin blockade by neutralizing antibody as well as cyclic-RGD peptides has been demonstrated to regulate cell proliferation by causing an inhibition of ILK activity and phosphorylation of AKT in ovarian cancer cells (Cruet-Hennequart et al., 2003) .
In human breast cancer cells, Taxol treatment at the clinical relevant concentration induces expression of the tumor suppressor protein p53 (Blagosklonny et al., 1995; Giannakakau et al., 2001) . Our experimental observations indicate that CYR61 expression may protect breast cancer cells from Taxol-induced apoptosis by regulating p53 function. Moreover, our experimental observations strongly suggest that overexpression of CYR61, through its a v b 3 integrin receptor, may inhibit the function of wild-type p53 in MCF-7 cells in an ERK1/ERK2 MAPK-related manner. Thus, functional blockade of a v b 3 completely restores the ability of CYR61-overexpressing breast cancer cells to upregulate p53 following Taxol exposure, and concurrently enhances Taxol-induced apoptotic cell death. Interestingly, pharmacological inhibition of ERK1/ERK2 MAPK activity by U0126 recapitulates the effects of a v b 3 integrin antagonists on Taxol-induced p53 accumulation and apoptosis in CYR61-overexpressing breast cancer cells. Recent studies have revealed that the combination of Taxol, which alters microtubule polymerization and activates ERK1/ERK2, and U0126, which inhibits MEK1/MEK-ERK1/ERK2 activity in the presence of Taxol, results in an impressive enhancement of tumor cell killing in several cancer models (MacKeigan et al., 2000 (MacKeigan et al., , 2002 McDaid and Horwitz, 2001; Seidman et al., 2001; Yu et al., 2001) . Our current results point towards the following model for the role of CYR61, a v b 3 , and ERK1/ERK2 MAPK in breast cancer chemosensitivity to Taxol. CYR61 overexpression, through its integrin receptor a v b 3 , induces the activation of the Raf-MEK1/MEK2-ERK1/ERK2 cascade, which may promote proliferation, growth, and survival. Taxol also induces the stimulation of the MEK1/MEK2-ERK1/ERK2 pathway. Alone, a v b 3 integrin antagonists operate like MEK inhibitors, thus blocking CYR61-promoted breast cancer cell proliferation and survival by interfering with ERK2/ERK2 activation. In combination, Taxol and a v b 3 integrin antagonists leads to enhanced breast cancer cell apoptosis, and a component of this enhanced apoptosis is attributable to the capacity of a v b 3 integrin antagonists to block the Raf-MEK1/MEK2-ERK1/ ERK2 cascade, which can protect cells against the toxic effects of Taxol (Rasouli-Nia et al., 1998; MacKeigan et al., 2000 MacKeigan et al., , 2002 . Although the ultimate role of p53 in this working model remains elusive, our observations suggest that overexpression of CYR61, in a a v b 3 -dependent manner, inhibits the function of wild-type p53 in MCF-7 cells, which could contribute to their acquired resistance to Taxol. In agreement with this hypothesis, O'Kelly et al. (2002) suggested that a lack of functional p53 may be a plausible mechanism through which CYR61 overexpression confers resistance to growth inhibition by TNFa.
Since CYR61 overexpression by itself activates the expression of the CYR61 integrin receptor a v b 3 , upregulation of CYR61 in the epithelial compartment of breast carcinoma may coordinate a metastatic phenotype in an autocrine manner by activating proliferative (i.e. ERK1/ERK2 MAPK) and antiapoptotic (i.e. AKT) signaling pathways, thus predisposing breast tumor epithelial cells towards deregulated proliferation and enhanced chemoresistance (Figure 9 ). Moreover, given that the CYR61 is also an important growth factor regulator in the endothelial compartment of breast carcinoma, it is reasonable to offer a novel hypothetical model in which CYR61 may drive breast tumorigenesis and progression in several concerted modes: (1) by regulating endothelial cell survival and recruitment during tumor neovascularization in a paracrine fashion through an a v b 3 -dependent mechanism; (2) by coordinating breast tumor epithelial cell migration as a chemokinetic factor; (3) by promoting breast cancer epithelial cell proliferation in an autocrine/ paracrine fashion either augmenting the bioactivity of other growth factors (i.e. EGFR); and (4) by enhancing breast cancer epithelial cell survival and chemoresistance through activation of prosurvival signaling pathways (ERK1/ERK2 MAPK and/or PI-3 0 K/AKT) downstream of a v b 3 . From a clinical perspective, our description of a novel CYR61-triggered 'CYR61-a v b 3 autocrine loop' in breast epithelial cancer cells, together with the cytotoxic and chemosensitizing effects of small peptidomimetic antagonists of a v b 3 towards CYR61-overexpressing breast cancer epithelial cells, provide a starting point to further evaluate the use of agents such as integrin antagonists that should permit a potentially synergistic strike against the breast tumor and its supporting vasculature.
Materials and methods
Cell culture
MCF-7 breast cancer cells were obtained from the American Type Culture Collection (ATCC) and they were routinely grown in phenol red-containing improved MEM (IMEM, Biosource International, Camarillo, CA, USA) supplemented with 5% (v/v) fetal bovine serum (FBS) and 2 mM L-glutamine at 371C in a humidified atmosphere of 95% air and 5% CO 2 . MCF-7 human breast cancer cells were engineered to overexpress CYR61 as previously described (Tsai et al., 2002) .
Briefly, MCF-7 cells were stably transfected by electroporation with a eucaryotic expression vector pcDNA3.1/zeocine(À) containing the full-length cDNA of the human CYR61 gene, or with an empty vector as a negative control. Transfected MCF-7 cells were selected in the presence of antibiotic zeocine (200 mg/ml) for 2 weeks. Since CYR61 mRNA and protein expression as well as cellular behavior did not vary significantly and was similar in most of the clones, a representative vector (V3-2) and two clones (C2-6 and C2-9) were chosen for the current studies. They were grown as indicated above, except than 200 mg/ml of zeocine was added to the culture medium.
To block CYR61 expression, a eucaryotic expression vector pcDNA3.1/zeocine(À) was constructed with the CYR61 cDNA oriented from 3 0 to 5 0 end, that is, in an antisense direction, and subsequently transfected into HRG-overexpressing MCF-7/T7 cells, a breast cancer progression model previously developed in our laboratory by transfecting the full-length HRG-b 2 cDNA into nonmetastatic MCF-7 breast cancer cells (Staebler et al., 1994; Harris et al., 1998) . Several CYR61 antisense (T7/CYR61-AS) clones were isolated and the presence of antisense CYR61 mRNA was confirmed by the RNAse protection assay (data not shown). Also generated were multiple clones of vector-transfected MCF-7/T7 (T7/AC-V) cells, all of which behaved similarly to the wild-type MCF-7/T7 clone. Two T7/CYR61-AS clones (T7/CYR61-AS4 and T7/CYR61-AS7) and one vector clone (T7/AC-V1) were characterized further. They were grown as indicated above, except that 200 mg/ml of zeocine was added to the culture medium.
Materials
The primary antibody for CYR61 immunoblotting was a rabbit polyclonal antibody (ab2026) from Novus Biologicals, Inc. (Littleton, CO, USA). Anti-a v b 3 mouse monoclonal antibody (clone LM609) was from Chemicon International (Temecula, CA, USA). Anti-ERK1/2 MAPK, P-ERK1/2 MAPK, AKT, and P-AKT Ser473 rabbit polyclonal antibodies were from Cell Signal Technology (Beverly, MD, USA). Antip53 mouse monoclonal antibody (clone Ab-5) and anti-b-actin goat polyclonal antibody were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The activation status of p185 HerÀ2/neu was characterized using a Her-2/neu phosphorylation statespecific antibody (Ab-18, PN2A clone; Lab Vision-NeoMarkers, Fremont, CA, USA).
Six small peptidomimetics antagonists of a v b 3 containing the RGD (Arg-Gly-Asp) motif (SC56631, SC68448, were developed based on a structure-activity relationship-based rational medicinal chemistry as previously described (Griggs et al., 2001; Meyer et al., 2001) . Briefly, human placenta-derived a v b 3 or human platelet-derived a IIb b 3 were bound to 96-well microtiter plates and incubated with human plasma-derived vitronectin conjugated to biotin for detection purposes. Densitometric determination after coincubation of the labeled ligand with a competitor provides data that when analysed using four-parameter fitting techniques yields the IC 50 (Table 1) . In all, 2 mM stock solutions in sterile water were stored at 41C until use. LY29400, a specific inhibitor of the p110 catalytic subunit of PI-3 0 K, and the MEK1/MEK2 inhibitor U0126 were purchased from Calbiochem (San Diego, CA, USA), dissolved in DMSO, and stored in the dark as 10 mM stock solutions at À201C until use. For experimental use, Taxol, SC56631, SC68448, S-247, S-196, S-205, S-106, LY294002, and U0126 were freshly prepared from stock solutions and diluted with growth medium. Control cells were cultured in medium containing the same concentrations of DMSO (v/v) or sterile water (v/v) as the experimental cultures with Taxol, LY294002, and U0126 or SC56631, SC68448, S-247, S-196, S-205, and S-106, respectively. Both DMSO and sterile water had no harmful effects on the proliferation or experimental cells. Immunoblotting analysis of CYR61 in cell supernatants Subconfluent human breast cancer cells were maintained in serum-free media for 48 h. The conditioned media were collected, concentrated 20 Â , and resolved by 10% Trisglycine SDS-PAGE. The separated proteins were electroblotted onto a Hybond enhanced chemiluminiscence nitrocellulose membrane (Amersham-Pharmacia). The blotted membrane was blocked overnight at 41C with 5% (w/v) bovine serum albumin (BSA) in Tris-buffered saline containing 0.5% Tween 20 (TBS-T), and then incubated with a rabbit anti-CYR61 polyclonal antibody (1 : 2000 dilution) for 1 h at room temperature. After three washes with TBS-T, the blot was incubated with a 1 : 10 000 dilution of horseradish peroxidase-linked donkey anti-rabbit IgG secondary antibody. The CYR61 protein was detected by the enhanced chemiluminiscence reaction using Hyperfilm (AmershamPharmacia).
Immunoblotting analysis of a v b 3 , ERK1/ERK2, P-ERK1/ERK2, AKT, P-AKT, p53, and P-p185
HerÀ2/neu Experimental cells were washed two times with PBS and then lysed in buffer (20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM b-glycerolphosphate, 1 mM Na 3 VO 4 , 1 mg/ml Leupeptin, 1 mM phenylmethylsulfonylfluoride) for 30 min on ice. The lysates were cleared by centrifugation in an eppendorff tube (15 min at 14 000 r.p.m., 41C). Protein content was determined against a standardized control using the Pierce protein assay kit (Rockford, IL, USA). Equal amounts of protein were resuspended in 5 Â Laemmli sample buffer for 10 min at 701C, subjected to electrophoresis on 10% SDS-PAGE (a v b 3 , ERK1/ERK2, P-ERK1/ERK2, AKT, P-AKT, and p53) or 3-8% Tris-Acetate NuPAGE (P-p185 HerÀ2/neu ) and transferred to nitrocellulose membranes. Nonspecific binding on the nitrocellulose filter paper was minimized by blocking for 1 h at room temperature (RT) with TBS-T (25 mM TrisHCl, 150 mM NaCl (pH 7.5), and 0.05% Tween 20) containing 5% (w/v) nonfat dry milk. The treated filters were washed in TBS-T and then incubated overnight at 41C with specific primary antibodies in TBS-T/5% (w/v) BSA. The membranes were washed in TBS-T, horseradish peroxidase-conjugated secondary antibodies (Jackson Immunoresearch Labs, West Grove, PA, USA) in TBS-T were added for 1 h, and immunoreactive bands were detected by enhanced chemiluminescence reagent (Pierce, Rockford, IL, USA). Blots were reprobed with an antibody for b-actin to control for protein loading and transfer.
Flow cytometric quantification of a v b 3 integrin
The specific surface expression of a v b 3 was determined by flow cytometry by measuring the binding of a mouse anti-a v b 3 antibody (clone LM609; Chemicon International). In total, 60-70% confluent overnight serum-starved cells were washed once with cold PBS and harvested by scrapping in cold PBS. The cells were pelleted and resuspended in cold PBS containing 1% FBS. The cells were then incubated with anti-a v b 3 antibody LM609 at 5 mg/ml for 1 h at 41C. After this, the cells were washed twice with cold PBS, resuspended in cold PBS containing 1% FBS, and then incubated with a fluorescein isothiocyanate (FITC)-conjugated anti-mouse IgG secondary antibody (Jackson Immunoresearch Labs, West Grove, PA, USA) diluted 1 : 200 in cold PBS containing 1% FBS for 45 min at 41C. Finally, the cells were washed once in cold PBS, and flow cytometric analysis was performed with a FACScan flow cytometer (Becton Dickinson, San Diego, CA, USA) equipped with Cell Quest Software (Becton Dickinson). The mean fluorescence signal associated with cells for labeled a v b 3 was quantified using the GM fluorescence parameter provided with the software.
In situ immunofluorescent staining of a v b 3 integrin Cells were seeded at a density of 2 Â 10 3 cells/well in an eightwell chamber slide (Nalge Nunc International, Rochester, NY, USA). Following an overnight period of serum-starvation, cells were washed with PBS, fixed with 4% paraformaldehyde in PBS for 10 min, permeabilized with 0.2% Triton X-100/PBS for 15 min, and stored overnight at 41C with 10% horse serum in PBS. The cells were washed, and then incubated for 1 h with anti-a v b 3 monoclonal antibody diluted in 0.05% Triton X-100/ PBS. After extensive washes, the cells were incubated for 45 min with an FITC-conjugated anti-mouse IgG secondary antibody (Jackson Immunoresearch Labs, West Grove, PA, USA) diluted 1 : 200 in 0.05% Triton X-100/PBS. The cells were washed five times with PBS and mounted with VECTASHIELD þ DAPI (Vector Laboratories, Burlingame, CA, USA). As controls, cells were stained with primary or secondary antibody alone. Control experiments did not display significant fluorescence in any case (data not shown). Indirect immunofluorescence was recorded on a Zeiss microscope. Images were noise-filtered, corrected for background, and prepared using Adobe Photoshop.
Cell viability
Cell viability was determined using a modified MTT reduction assay (Cell Titer 96 Aqueous Non-Radioactive Cell Proliferation Assay, Promega Inc., Madison, WI, USA). Briefly, cells in exponential growth were harvested by trypsinization and seeded at a concentration of 3 Â 10 3 cells/200 ml/well into 96-well plates, and allowed an overnight period for attachment. Then the medium was removed and fresh medium along with graded concentrations of a v b 3 integrin antagonists was added to cultures. Compounds were not renewed during the entire period of cell exposure. Following treatments (6-7 days), 96-well plates were centrifugated at 200 g for 10 min and MTS/ PMS solution was added to each well at a 1/5 volume. After incubation for 3 h at 371C in the dark, absorbances were measured at 490 nm using a multiwell plate reader. Control cells without agents were cultured using the same conditions with comparable media changes. Compounds were not renewed during the entire period of cell exposure. The cell viability effects from exposure of cells to each compound were analysed generating concentration-effect curves as a plot of the fraction of unaffected (surviving) cells versus drug concentration. Dose-response curves were plotted as percentages of the control cell absorbances, which were obtained from control wells treated with appropriate concentrations of the compounds vehicles that were processed simultaneously. For each treatment, cell viability was evaluated as a percentage using the following equation: (A 570 of treated sample/A 570 of untreated sample) Â 100. Data presented summarize the mean (7s.d.) of five independent experiments made in triplicate. Breast cancer cells sensitivity to a v b 3 integrin antagonists was expressed in terms of the concentration of antagonist required for either 30 or 50% (IC 30 and IC 50 ) reduction of cell viability. Since the percentage of control absorbance was considered to be the surviving fraction of cells, the IC 30 and IC 50 values were defined as the concentration of drug that produced 30 and 50% reduction in control absorbance (by interpolation), respectively.
Synergy analysis
The nature of the cytotoxic interaction between a v b 3 integrin antagonists and Taxol was evaluated by the isobologram technique, a dose-oriented geometric method of assessing drug interactions (Berenbaum, 1989) . Briefly, the concentration of one agent producing a desired (e.g. 50% inhibitory) effect was plotted on the horizontal axis (a v b 3 integrin antagonist), and the concentration of another agent producing the same degree of effect was plotted on the vertical axis (Taxol); a straight line joining these two points represents zero interaction (additivity) between two agents. The experimental isoeffect points are the concentrations (expressed relative to the IC 50 concentrations) of the two agents which when combined killed 50% of the cells. When the experimental isoeffect points fall below that line, the combination effect of the two drugs is considered to be supra-additive or synergistic, whereas antagonism occurs if the point lies above it. A quantitative index of these interactions was provided by the isobologram equation CI x ¼ (a/A) þ (b/B), where, for this study, A and B represent the respective concentrations of a v b 3 antagonist and Taxol required to produce a fixed level of inhibition (IC 50 ) when administered alone, a and b represent the concentrations required for the same effect when the drugs were administered in combination, and CI x represents an index of drug interaction (interaction index). CI x values of o1 indicate synergy, a value of 1 represents addition, and values of >1 indicate antagonism.
Soft-agar colony formation assays
For Taxol sensitivity assays, 1 ml of 0.6% agar in phenol-redcontaining IMEM supplemented with 10% FBS was solidified in the bottom of six-well culture dishes. Exponentially growing cells to be assayed were suspended at 421C in 1 ml of 0.3% agar in complete medium (10% FBS) supplemented with graded concentrations of Taxol. A total of 20 000 cells were seeded in each well. For estrogen-dependent soft agar colony formation assays, cells were grown in phenol-red-free IMEM and 5% charcoal-treated calf serum (CCS) for 5 days in T75 flasks. A bottom layer of 1 ml IMEM containing 0.6% agar and 10% CCS was prepared in six-well culture dishes. After the bottom layer solidified, cells (20 000/well) were added in a 1 ml top layer containing E 2 -depleted 10% CCS. After 2 weeks of incubation at 371C in 5% CO 2 and 95% air, colonies measuring X50 mm were counted after staining with nitroblue tetrazolium (Sigma, St Louis, MO, USA) using a cell colony counter (Ommias 3600, Imaging Products International, Inc., Charley, VA, USA).
Cell death ELISA
The induction of cell death was assessed using the Cell Death Detection ELISA PLUS kit obtained from Roche Molecular Biochemicals USA (Indianapolis, IN, USA) . This kit uses a photometric enzyme immunoassay that quantitatively determines the formation of cytoplasmic histone-associated DNA fragments (mono-and oligonucleosomes) after apoptotic cell death. Briefly, cells (7.5 Â 10 3 /well) were grown in 96-well plates and treated, in duplicates, for 24 h with 10 nM Taxol. The induction of apoptotic cell death was evaluated using cytosolic fractions obtained from pooled adherent and floating cells (obtained by centrifugation at 200g for 10 min) by assessing the enrichment of nucleosomes in the cytoplasm using anti-histone biotin and anti-DNA peroxidase antibodies (RT for 2 h), and determined exactly as described in the manufacturer's protocol. After three washes, the peroxidase substrate was added to each well, and the plates were read at 405 nm at multiple time intervals. The enrichment of histone-DNA fragments in treated cells was expressed as fold increase in absorbance as compared with control (vehicle-treated) cells.
TUNEL assay
Detection of apoptosis by analysis was performed using the DeadEnd TM Fluorometric TUNEL System (Promega Inc., Madison, WI, USA) according to the manufacturer's instructions. Briefly, cells were split at a density of 1 Â 10 4 cells/well in eight-well chamber slides (Lab-Tek). Following 24 h incubation, the cells were treated with 10 nM Taxol in the absence or presence of 0.5 mM S-247 for 24 h. Following treatments, cells were washed twice with PBS and fixed with 4% methanol-free paraformaldehyde for 10 min. Cells were washed twice more with PBS and permeabilized with 0.2% Triton X-100 for 5 min. After two more washes, each slide was covered with equilibration buffer for 10 min more. The buffer was then aspirated, and the slides were incubated with TdT buffer at 371C for 1 h. The reaction was stopped with 2 Â SSC, counterstained with DAPI, and the slides were viewed with an immunofluorescence microscope (Zeiss).
Cell cycle analysis
Adherent and detached cells were collected after trypsin detachment, washed in PBS and centrifugated at 1500 r.p.m. Cells were resuspended at 2 Â 10 6 cells/ml in PBS and fixed in ice-cold 70% ethanol for, at least, 24 h. Fixed cells were centrifugated at 1500 r.p.m., and each sample resuspended in propidium iodide (PI) stain buffer (0.1% Triton X-100, 200 mg of DNase-free RNase A, 20 mg of PI) in PBS for 30 min. After staining, samples were analysed using a FACScan (Becton Dickinson) and ModFit LT (Verity Software).
Statistical analysis
All observations were confirmed by at least three, independent experiments. The data are presented as means7s.d. The Student's t test (paired and unpaired) was used to evaluate the statistical significance of mean values. Statistical significance levels were Po0.05 (denoted as*) and Po0.005 (denoted as**). All Ps are two-tailed.
